News & Events

• December 3, 2020
  

  C-Path Selects Aridhia to Support Rare Disease Cures Accelerator-Data and Analytics Platform

    TUCSON, Ariz., December 3, 2020 — The Critical Path Institute (C-Path) today announced it has selected Aridhia to support its Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP). The RDCA-DAP initiative, launched in September 2019 as a collaborative project between C-Path and the National Organization for Rare Disorders® (NORD), will provide a centralized and...
• October 28, 2020
  

  C-Path and EATRIS To Collaborate on RDCA-DAP

  C-Path has signed a Memorandum of Understanding with EATRIS, the European infrastructure for translational medicine, to accelerate drug development for rare diseases by increasing the efficiency of translation of potential therapeutics through preclinical and clinical development …

• October 21, 2020
  

  Rare Disease Cures Accelerator-Data and Analytics Platform First Year Milestones Highlighted at Virtual Workshop

      C-Path, NORD, FDA and more come together to showcase the importance of data sharing in rare disease drug development   TUCSON, Ariz. and WASHINGTON, D.C. October 21, 2020 — The Critical Path Institute (C-Path) and the National Organization for Rare Disorders (NORD®) hosted the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP) 2020 Virtual Workshop on...
• September 19, 2019
  

  Innovative Data and Analytics Platform to Accelerate Drug Development for Rare Diseases

  Launched by C-Path and NORD through an FDA grant, the goal of the new platform is to accelerate the development of cures by addressing the need to better characterize rare diseases.

• August 7, 2019
  

  Funded by FDA, C-Path and NORD to Launch Rare Disease Data and Analytics Platform

  C-Path and NORD Rare Disease Cures Accelerator Data Analytics Platform Launch, Tuesday, Sept. 17, Bethesda, MD

  C-Path and the National Organization for Rare Disorders® will host a meeting to formally launch development of a new rare disease data and analytics platform. Funded by a cooperative agreement through the U.S. Food and Drug Administration, the goal of the platform is to accelerate the movement of therapies from bench to bedside for rare diseases. Register here.